tg4010
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01383148)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Mucin-1Immunity, active
MUC1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tg4010
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03353675 | Phase 2 | Jan 16, 2018 | Bristol-Myers Squibb, Transgene |
| NCT02823990 | Phase 2 | Dec 1, 2016 | Bristol-Myers Squibb, National Cancer Institute (NCI), Transgene, University of California, Davis |
| NCT01383148 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2012 | Transgene |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Transgene | For profit | 3 | 2 | 2 | 2012 |
| Bristol-Myers Squibb | For profit | 2 | 0 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1